Updates

SECOND OPINION: PHRMA STUDY REHASHES DEBUNKED SUPPLY CHAIN BLAME GAMES

Feb 3, 2022

Big Pharma Sidesteps Industry’s Own Price Hikes and Egregious Practices in Read More

CSRXP: BIG PHARMA’S BUSINESS-AS-USUAL APPROACH TO JANUARY PRICE HIKES UNDERSCORES URGENCY FOR RX SOLUTIONS

Feb 2, 2022

Drug Companies Increased Prices on 785 Brand Name Products in First Month of Read More

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Jan 28, 2022

J&J Surpasses Wall Street Expectations, Nearly Tripling Year-Over-Year Read More

ICYMI: NEW REPORTS UNDERSCORE URGENCY FOR ACTION TO REIN IN BIG PHARMA’S OUT-OF-CONTROL DRUG PRICES

Jan 21, 2022

CBO Finds Net Prices for Brand Name Drugs More Than Doubled from 2009-2018; Read More

DOSE OF REALITY: NEW ANALYSIS UNDERSCORES HOW OFTEN BIG PHARMA’S PATENTS ARE UNRELATED TO CLINICAL INNOVATION

Jan 19, 2022

Study Finds Just Six Percent of Drug Patents in Infringement Suits Were for Read More

CSRXP STATEMENT ON PROPOSED CMS COVERAGE DECISION FOR ADUHELM

Jan 12, 2022

DECISION WILL HELP PROTECT SENIORS, TAXPAYERS AND THE U.S. HEALTH SYSTEM FROM Read More

CSRXP STATEMENT AHEAD OF COMMITTEE VOTE FOR DR. ROBERT CALIFF TO LEAD U.S. FOOD AND DRUG ADMINISTRATION

Jan 12, 2022

Next FDA Commissioner Must Promote Competition, Transparency And Value In The Read More

SECOND OPINION: BIG PHARMA CEO CLAIMS “COURAGEOUS” TO PRICE UNPROVEN TREATMENT 10 TIMES ESTIMATE OF FAIR PRICE

Jan 11, 2022

Biogen Decision to Change Aduhelm Price After Public Outcry Demonstrates Big Read More

BIG PHARMA WATCH: BIG PHARMA’S JANUARY PRICE HIKES CLIMB TO 588

Jan 7, 2022

Brand Name Drug Companies’ Business-as-Usual Approach to Price Increases Read More

HAPPY NEW YEAR: BIG PHARMA HIKES PRICES ON MORE THAN 400 BRAND NAME DRUGS TO RING IN 2022

Jan 3, 2022

Fourth Major Round Of Pandemic Price Hikes Highlight Urgency for Policymakers Read More

DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART I

Dec 28, 2021

Part I: Price-Gouging An Unproven Treatment, Setting Out-of-Control Launch Read More

DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART II

Dec 28, 2021

Part II: Pushing Debunked Innovation Rhetoric to Oppose Rx Solutions Despite Read More